undamentalytics Newsletter
Sign in

Zymeworks Inc. income statement

In fiscal 2025, Zymeworks Inc. reported revenue of $106m, up 38.9% on the year before, operating income of −$92.5m (a -87.3% margin) and net income of −$81.1m, or −$1.08 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue3927412767610637
Research and development171200209144135137129
General and administrative55437370626264
Operating income−187−216131−138−137−93−156
Income before tax−180−212135−119−117−80−151
Income tax0−111−161−1
Net income−181−212124−119−123−81−150
Diluted EPS−$3.58−$4.61$1.90−$1.72−$1.62−$1.08−$2.02
Diluted shares (average)50m52m65m69m76m75m74m
EBITDA−184−212137−131−133−89−152

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: NBTX vs ZYMEFHTX vs ZYMECUE vs ZYME

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Zymeworks Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Zymeworks Inc.